-
公开(公告)号：EP3402821A1
公开(公告)日：2018-11-21
申请号：EP17701290.3
申请日：2017-01-16
申请人： Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts , Eberhard Karls Universität Tübingen
CPC分类号： C07K16/3069 , C07K16/2809 , C07K16/3084 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2317/73
摘要： The present invention provides a novel PSMA binding antibody termed 10B3 and pharmaceutical and diagnostic uses of the antibody 10B3. The PSMA antibody 10B3 does not cross-compete with the state of the art PMSA binding antibody J591 and has a reduced induction of antigen shift compared to J591 and a unique reactivity with squamous cell carcinoma (SCC) cells of different origin.
-
公开(公告)号：EP4061841A1
公开(公告)日：2022-09-28
申请号：EP20807391.6
申请日：2020-11-18
申请人： Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts , Eberhard-Karls-Universität Tübingen
-
公开(公告)号：EP3850010A1
公开(公告)日：2021-07-21
申请号：EP19765489.0
申请日：2019-09-11
申请人： Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts , Eberhard-Karls-Universität Tübingen
-
公开(公告)号：EP4240762A1
公开(公告)日：2023-09-13
申请号：EP21805504.4
申请日：2021-11-03
申请人： Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts , Eberhard-Karls-Universität Tübingen
发明人： SALIH, Helmut , JUNG, Gundram , PFLÜGLER, Martin , ZEKRI, Latifa , MANZ, Timo
-
公开(公告)号：EP1781317A1
公开(公告)日：2007-05-09
申请号：EP05782884.0
申请日：2005-08-19
发明人： STUHLER, Gernot , SALIH, Helmut
CPC分类号： G01N33/57496 , A61K38/16 , A61K38/43 , C12Q1/485
摘要： The present invention relates to a therapeutic or/and diagnostic substance. Furthermore it relates to an expression vector, to a composition comprising the afore-mentioned substance or/and the afore-mentioned expression vector, a method for diagnosing a tumor disease or/and an infectious disease in a living being, as well as to a method for the treatment of a tumor disease or/and of an infection in a living being.
-
公开(公告)号：EP3227331A1
公开(公告)日：2017-10-11
申请号：EP15813700.0
申请日：2015-11-23
发明人： JUNG, Gundram , SALIH, Helmut , VOGT, Fabian , KAUER, Joseph
IPC分类号： C07K16/24 , A61K39/395
CPC分类号： C07K16/2845 , A61K35/17 , A61K2035/124 , C07K16/24 , C07K16/241 , C07K16/2803 , C07K16/2806 , C07K16/2809 , C07K16/2821 , C07K16/2827 , C07K16/2863 , C07K16/2866 , C07K16/2896 , C07K16/3069 , C07K2317/24 , C07K2317/31 , C07K2317/76 , C07K2319/02 , G01N33/56972 , G01N2500/02 , G01N2500/10
摘要： The present invention relates to a blocking-reagent for use in reducing unspecific T cell activation in T cell engaging therapies. The present invention further relates to pharmaceutical kit of parts and an in vitro method for evaluating unspecific T cell activation.
摘要翻译： 本发明涉及用于减少T细胞参与治疗中的非特异性T细胞活化的阻断剂。 本发明还涉及用于评估非特异性T细胞活化的部分药物试剂盒和体外方法。
-
7.发明公开FUSION PROTEINS COMPRISING A BINDING PROTEIN AND AN INTERLEUKIN-15 POLYPEPTIDE HAVING A REDUCED AFFINITY FOR IL15Ra AND THERAPEUTIC USES THEREOF 审中-公开包含结合蛋白和IL15Rα降低亲和力的IL-15多肽的融合蛋白及其治疗用途
公开(公告)号：EP3265478A1
公开(公告)日：2018-01-10
申请号：EP16708154.6
申请日：2016-03-07
CPC分类号： C07K14/5443 , A61K38/00 , C07K16/2803 , C07K16/3069 , C07K2317/41 , C07K2317/526 , C07K2317/72 , C07K2317/732 , C07K2319/00 , C07K2319/33 , C07K2319/74 , C07K2319/75
摘要： The present invention relates to fusion proteins comprising a binding protein and an IL-15 polypeptide as well as uses thereof, pharmaceutical compositions comprising such fusion proteins and a method for producing such fusion proteins.
-
公开(公告)号：EP3265478B1
公开(公告)日：2019-09-11
申请号：EP16708154.6
申请日：2016-03-07
-
公开(公告)号：EP3192810A1
公开(公告)日：2017-07-19
申请号：EP16151281.9
申请日：2016-01-14
CPC分类号： C07K16/3069 , C07K16/2809 , C07K16/3084 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2317/73
摘要： The present invention provides a novel PSMA binding antibody termed 10B3 and pharmaceutical and diagnostic uses of the antibody 10B3. The PSMA antibody 10B3 does not cross-compete with the state of the art PMSA binding antibody J591 and has a reduced induction of antigen shift compared to J591 and a unique reactivity with squamous cell carcinoma (SCC) cells of different origin.
摘要翻译： 本发明提供称为10B3的新型PSMA结合抗体和抗体10B3的药物和诊断用途。 PSMA抗体10B3不与现有技术的PMSA结合抗体J591交叉竞争，并且与J591相比具有减少的抗原转移诱导以及与不同来源的鳞状细胞癌（SCC）细胞的独特反应性。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.02 秒)
